Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: A long-term follow-up study of the US intergroup phase III trial E2997

David M. Lucas, Amy S. Ruppert, Gerard Lozanski, Gordon W. Dewald, Arletta Lozanski, Rainer Claus, Christoph Plass, Ian W. Flinn, Donna S. Neuberg, Elisabeth M. Paietta, John M. Bennett, Diane F. Jelinek, John G. Gribben, Mohamad A. Hussein, Frederick R. Appelbaum, Richard A. Larson, Dennis F. Moore, Martin S. Tallman, John C. Byrd, Michael R. Grever

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: A long-term follow-up study of the US intergroup phase III trial E2997'. Together they form a unique fingerprint.

Medicine & Life Sciences